Angiography

Breakthrough Study Reveals Somavedic Device's Potential Impact on Wet AMD Patients

Retrieved on: 
Tuesday, April 23, 2024
AMD, Patient, CNV, Health, Angiography, Research, OCT, CRT, Quality of life, Sleep, SAN, Visual acuity

SAN FRANCISCO, April 23, 2024 /PRNewswire/ -- Somavedic, a trailblazer in sleep and digital pollution-neutralizing frequency therapy technology, in collaboration with researchers from the Eye Clinic of Jan Evangelista Purkyně University and Masaryk Hospital in Ústí nad Labem in the Czech Republic, have unveiled groundbreaking findings from a study showcasing the effectiveness of the Somavedic device in supporting individuals with wet age-related macular degeneration (wet AMD), a prevalent cause of severe vision impairment among older adults.

Key Points: 
  • The study enrolled patients with newly diagnosed wet AMD and active choroidal neovascularization (CNV), where anti-VEGF therapy was indicated.
  • Patients received a functioning Somavedic device for home use, while the other group was administered a non-functional placebo device.
  • "We are immensely encouraged by the positive outcomes of this study, which underscore the potential of Somavedic to make a meaningful impact on the lives of individuals affected by wet age-related macular degeneration.
  • The positive outcomes of this study pave the way for larger-scale clinical trials to substantiate the efficacy of Somavedic in wet AMD management.

iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

Retrieved on: 
Monday, April 8, 2024
Prevalence, Cardiovascular disease, Sudden death, Radiology, Blood, Risk, Physician, ICAD, Patient, Ageing, Stroke, Research, Breast, Angiography, Death, Woman, American College, Breast cancer, Literature, Prognosis, Moyamoya disease, ACC, Medical imaging

The 15-site prospective study included 2D screening mammograms from women ages 20 to 100, with a median age of 56.

Key Points: 
  • The 15-site prospective study included 2D screening mammograms from women ages 20 to 100, with a median age of 56.
  • “The ProFound BAC AI algorithm may provide a critical surrogate biomarker for women at risk of heart disease or stroke,” said Dana Brown, president and CEO of iCAD.
  • The study also suggests the ProFound Heart Health AI algorithm can standardize BAC detection, potentially improving efficiency and reducing variability among observers.
  • Early cardiovascular disease detection is key, as among asymptomatic women, the first manifestation of underlying coronary heart disease is often acute myocardial infarction (MI) or sudden death.

Europe Contrast Media Agent and Injector System Analysis Report 2024: Increasing Prevalence of Cancer and Cardiovascular Diseases Leading to Upsurge in Demand - Forecasts to 2033 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 7, 2024
General Health, Health, Medical Supplies, Medical Devices, Name, Angiography, Ageing, Growth, Conditional sentence, Prevalence, Diagnosis, Research, MRI, Cancer, Partnership, Medical imaging

The "Europe Contrast Media Agent and Injector System Market: Analysis and Forecast: 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Contrast Media Agent and Injector System Market: Analysis and Forecast: 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • The Europe Contrast Media Agent and Injector System market is witnessing robust growth driven by factors such as the increasing prevalence of chronic diseases, rising demand for diagnostic imaging procedures, and advancements in medical imaging technologies.
  • Growth/Marketing Strategy: The Europe contrast media agent and injector system market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint ventures.
  • Competitive Strategy: The Europe contrast media agent and injector system market consists of various leading manufacturers, small-medium enterprises, and emerging startups.

Injectable Angioplasty Balloon Catheter Transforms Peripheral Procedures, Users Report Reduced Equipment and Contrast Needs

Retrieved on: 
Wednesday, January 17, 2024
Medical Devices, Surgery, FDA, Clinical Trials, Cardiology, Practice Management, Other Health, Biotechnology, Radiology, Health, Diabetes, Patient, Amputation, Kidney, Calf, Knee, Finesse, Angiography, Multimedia, DRS, Risk, Chronic kidney disease, Mount Sinai Hospital (Manhattan), PAD, Medical imaging

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    The Summa Finesse Injectable catheter is the industry’s first hybrid diagnostic and therapeutic angioplasty balloon catheter developed to facilitate treatment of patients at risk of limb loss due to below-knee PAD.
  • It was designed to improve the efficiency of peripheral angioplasty procedures by reducing equipment and contrast needs.
  • “In our busy limb salvage practice, it will be an important tool.”
    The Summa Finesse Injectable is a multifunctional catheter that serves as a crossing catheter, diagnostic angiography catheter, and angioplasty catheter to reduce equipment and contrast needs.
  • The Summa Finesse Injectable is the first hybrid catheter launched in the planned line of interventional radiology devices from Summa.

Global Cardiac Bio Implant Devices Market Size and Forecast Report 2023: A $60+ Billion Industry by 2030 - Growing Attractiveness of Bio-implant Treatments Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 15, 2024
Biotechnology, Health, Cardiology, Medical Devices, Ageing, Diabetes, Obesity, Moyamoya disease, American Heart Association, Woman, Arthroscopy, Beauty, Binge drinking, Incidence, Cardiac catheterization, CRT, Angiography, Smoking, Application, Heart failure, Element, Echocardiography, ISR, USD, Cardiac resynchronization therapy, IHD, Diagnosis, Prevalence, Medical device

The "Cardiac Bio Implant Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiac Bio Implant Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Cardiac Bio-Implants Device Market size is estimated to be US$ 60.20 Billion by 2030.
  • The global cardiac bio-implants market changed into worth USD 34.70 Billion in 2022.
  • The growth of the Cardiac Catheterization laboratory market is primarily fueled by the increasing prevalence of cardiovascular disorders and advancements in Cardiac Catheterization lab technology.

Prytime Medical Devices, Inc. Announces Appointment of Donna Syracuse as Chief Commercialization Officer

Retrieved on: 
Tuesday, November 21, 2023
SAN, Commercial, Cardiology, Intervention, Merit, Moyamoya disease, RN, Drainage, Patient, Dialysis, Region, Electrophysiology, NCTH, Nephrology, REBOA, Standard of care, Bleeding, Nursing care plan, Death, Growth, Hospital, Physician, Syracuse, Nursing, Angiography, Biopsy

SAN ANTONIO, Nov. 21, 2023 /PRNewswire-PRWeb/ -- Prytime Medical Devices Inc, The REBOA Company™, the leading innovator and global provider of lifesaving REBOA products for noncompressible torso hemorrhage (NCTH), announced that Donna Syracuse, RN, has joined the company as Chief Commercialization Officer effective August 28, 2023.

Key Points: 
  • Donna Syracuse has over 25 years of Commercial and Nursing Leadership in critical care, nephrology, cardiology, peripheral vascular disease, and electrophysiology.
  • Focused on clinical outcomes and evidence development, Donna was key in developing the HeRO® Graft market from launch to becoming Standard of Care for dialysis patients.
  • "I'm excited to join Prytime Medical at this point of its growth," said Donna.
  • "Donna's experience fits perfectly with Prytime's strategic goal for building outcomes-driven REBOA programs," said David Spencer, Prytime Medical CEO.

Second Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Tuesday, October 31, 2023
Blood vessel, Patient, Angiography, Isabella Tree, Peripheral artery disease, PTA, De novo, Artery, Education, Incidence, DCB, Ioctl, BMI, AVF, CLTI, Kaplan–Meier estimator, Kidney disease, Research, HIV disease progression rates, RCT, Wound healing, BRS, Dialysis, Thrombosis, Clinical trial, Extremities, Risk, Dural arteriovenous fistula, Magnitude, Classification, VIVA, IVUS, Amputation, BTK, PAD, Wynn Las Vegas, Infection, Medical imaging, Pharmaceutical industry, Silviculture

Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.
  • Results from Abbott's LIFE-BTK randomized clinical trial (RCT) demonstrate that Esprit BTK (Abbott) reduces disease progression and helps improve medical outcomes compared to balloon angioplasty, the current state of care.
  • In the LIFE-BTK trial, wound assessment was not a prespecified powered primary or secondary endpoint but rather a prespecified descriptive endpoint.
  • The trial offers the largest ischemic wound data set to date, collected systematically and adjudicated independently in a blinded fashion.

Accarent Health's Commitment: Ensuring Equal Access to Premium Cardiovascular Care

Retrieved on: 
Thursday, October 19, 2023
Angiography, Angioplasty, Najib Roger Accar, Certification, Percutaneous coronary intervention, Transport, Myocardial infarction, Risk, Hypertension, Aortic stenosis, Hospital, National Institute for Health and Care Excellence, Patient, Death, Cardiac catheterization, Pharmaceutical industry, Nursing, MD, Health

They also are less likely than non-minority patients to receive potentially beneficial treatments such as angiography or percutaneous coronary intervention.

Key Points: 
  • They also are less likely than non-minority patients to receive potentially beneficial treatments such as angiography or percutaneous coronary intervention.
  • In addition to improved awareness and better control of hypertension in minority populations, improved access to appropriate intervention is important to addressing these disparities.
  • Accarent Health is a unified technology and care management platform granting access to pre-negotiated, fixed bundled prices for complex medical procedures and treatments, eliminating unpredictable costs and providing increased access to quality care.
  • For more information or to access these or other cardiovascular treatment options visit Accarent Health at www.accarenthealth.com.

AccuLine Announces Know-How License Agreement with Mayo Clinic to Advance Early Detection of Heart Attacks

Retrieved on: 
Thursday, September 28, 2023
CT scan, Heart, Mayo Clinic, Education, Maccabi Healthcare Services, Moyamoya disease, CAD, Splenic infarction, Research, Angiography, Cardiology, Trial of the century, Practitioner, Physician, Mortality, Coronary artery disease, FDA, Health, Death, Pharmaceutical industry, Medical imaging, Medical device

As part of the agreement, Mayo Clinic will become a shareholder in AccuLine.

Key Points: 
  • As part of the agreement, Mayo Clinic will become a shareholder in AccuLine.
  • CAD stands as the leading trigger for heart attacks, which are the number one cause of death globally.
  • "We are thrilled to join forces with Mayo Clinic in this pivotal initiative aimed at reducing the impact of heart attacks on mortality and patient well-being.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

SpectraWAVE Secures 510(k) Clearance to Add Saline Imaging and Expanded Artificial Intelligence Features to the HyperVue™ Imaging System

Retrieved on: 
Tuesday, September 19, 2023
Technology, Medical Devices, Medical Supplies, FDA, Health Technology, Cardiology, Hardware, Health, Artificial Intelligence, Plaque, Blood vessel, Myocardial infarction, EEL, Fractional flow reserve, Food and Drug Administration, NIRS, CAD, Nasiriyah Heart Center, Intelligence, Multimedia, Angiography, Meta-analysis, Calcium, Congress, Acquisition, Patient, Physician, Risk, Algorithm, Artificial intelligence, St. Francis Hospital, Coronary artery disease, European Society of Cardiology, Arrest, Food, Medical imaging

The intravascular imaging system combines next-generation DeepOCT™ images and near infrared spectroscopy (NIRS) with state-of-the-art ease of use to support physicians optimizing coronary stenting in the cardiac catheterization lab.

Key Points: 
  • The intravascular imaging system combines next-generation DeepOCT™ images and near infrared spectroscopy (NIRS) with state-of-the-art ease of use to support physicians optimizing coronary stenting in the cardiac catheterization lab.
  • Newly cleared product enhancements include contrast-free saline imaging, artificial intelligence algorithms to support the identification of key clinical structures of calcium and external elastic lamina (EEL), and hands-free angiographic co-registration.
  • The latest clearance adds to the existing HyperVue toolkit , which includes artificial intelligence enabled lipid, lumen, stent, and sidebranch detection, as well as the no-flush prep Starlight™ Imaging Catheter designed for efficient setup and image acquisition in complex lesions.
  • Next generation DeepOCT and Near Infrared Spectroscopy intravascular imaging system now includes compatibility with contrast-free saline imaging, advanced artificial intelligence algorithms to identify calcium and external elastic lamina, and hands-free angiographic co-registration.